- Revenue for the second quarter of 2012 increased to $30.0 million, 25 percent above revenue of $24.1 million in the second quarter of 2011. US revenue increased 26 percent to $23.9 million and European revenue increased 16 percent to $5.1 million in the second quarter of 2012 compared to the second quarter of 2011.
- For the first six months of 2012, revenue increased to $59.9 million, or 29 percent above revenue of $46.4 million during the first six months of 2011.
- During the first six months of 2012, revenue from 1,507 new customer companies totaled $7.4 million and revenue from 3,858 existing customer companies totaled $52.5 million.
- Net income during the second quarter of 2012 totaled $5.1 million, or $0.20 per share. After adding back the after-tax expense of stock compensation, non-GAAP net income was $5.7 million, or $0.23 per share. See “Non-GAAP Financial Measure” below.
- Gross margin was 59.1 percent of revenue in the second quarter of 2012 compared with 60.4 percent in the second quarter of 2011.
- During the second quarter of 2012, spending on research and development, including the Protoworks initiatives, totaled $2.4 million, or 8.0 percent of revenue. This compares to $1.7 million, or 5.5 percent of revenue during the first quarter of 2012.
- Operating margin was 24.9 percent of revenue compared with 27.6 percent in the second quarter a year ago.
- Cash generated from operations totaled $11.5 million in the first six months of 2012 compared to $10.4 million during the same period in 2011.
- Expenditures on capital equipment were $12.7 million in the first half of 2012.
Non-GAAP Financial MeasureThe company has included non-GAAP net income, adjusted for stock-based compensation expense in this press release to provide investors with additional information regarding the company’s financial results. The company has provided below a reconciliation of non-GAAP net income, adjusted for stock-based compensation expense, to net income, the most directly comparable measure calculated and presented in accordance with GAAP. Non-GAAP net income, adjusted for stock-based compensation expense, is used by the company’s management and board of directors to understand and evaluate operating performance and trends and provides a useful measure for period-to-period comparisons of the company’s business. Accordingly, the company believes that non-GAAP net income, adjusted for stock-based compensation expense, provides useful information to investors and others in understanding and evaluating operating results in the same manner as our management and board of directors. Conference Call The company has scheduled a conference call to discuss its first quarter financial results today, July 24, at 8:30 a.m. ET. To access the call in the U.S. please dial 866-804-6922. Outside the U.S. please dial. 857-350-1668. Use participant code 85241974#. A simultaneous webcast of the call will also be available on the investor relations section of the company’s website at www.protolabs.com/investors. An audio replay will be available for 14 days following the call on the investor relations website of Proto Lab’s website. About Proto Labs, Inc. Proto Labs is a leading online and technology-enabled quick-turn manufacturer of custom parts for prototyping and short-run production. Proto Labs provides “Real Parts, Really Fast” to product developers worldwide. Proto Labs utilizes computer numerical control (CNC) machining and injection molding to manufacture custom parts for our customers. For more information, visit protolabs.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical or current facts are “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause the results of Proto Labs to be materially different than those expressed or implied in such statements. Certain of these risk factors and others are described in the “Risk Factors” section of the final prospectus relating to the Proto Labs’ initial public offering, as filed with the SEC, as well as in Proto Labs’ subsequent reports filed with the SEC. Other unknown or unpredictable factors also could have material adverse effects on Proto Labs’ future results. The forward-looking statements included in this press release are made only as of the date hereof. Proto Labs cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Proto Labs expressly disclaims any intent or obligation to update any forward-looking statements to reflect subsequent events or circumstances.
|Proto Labs, Inc. Condensed Consolidated Balance Sheets (In thousands)|
|June 30, 2012||December 31, 2011|
|Cash and cash equivalents||$||44,386||$||8,135|
|Short-term marketable securities||14,269||250|
|Accounts receivable, net||13,717||11,533|
|Other current assets||4,461||4,362|
|Total current assets||80,819||28,077|
|Property and equipment, net||44,083||34,249|
|Long-term marketable securities||20,073||-|
|Liabilities, redeemable convertible stock and|
|shareholder's equity (deficit)|
|Accrued liabilities and other||1,415||351|
|Current portion of long-term debt obligations||378||390|
|Total current liabilities||9,567||9,939|
|Deferred tax liability||4,252||4,252|
|Long-term debt obligations||432||613|
|Redeemable convertible preferred and common stock||-||66,894|
|Shareholders' equity (deficit)||129,909||(20,243||)|
|Total liabilities, redeemable convertible stock and shareholders' equity (deficit)||$||144,975||$||62,326|
|Proto Labs, Inc. Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) (Unaudited)|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Cost of revenues|
|Total cost of revenues||12,239||9,517||24,482||17,946|
|Marketing and sales||4,557||3,924||8,998||7,139|
|Research and development||2,401||1,223||4,061||2,335|
|General and administrative||3,288||2,753||7,276||5,259|
|Total operating expenses||10,246||7,900||20,335||14,733|
|Income from operations||7,466||6,635||15,104||13,708|
|Other income (expense), net||173||78||(404||)||(3||)|
|Income before income taxes||7,639||6,713||14,700||13,705|
|Provision for income taxes||2,493||2,182||4,772||4,451|
|Less: dividends on redeemable preferred stock||-||(1,042||)||-||(2,073||)|
|Less: undistributed earnings allocated to preferred shareholders||-||(1,160||)||-||(2,419||)|
|Net income attributable to common shareholders||$||5,146||$||2,329||$||9,928||$||4,762|
|Net income per share:|
|Shares used to compute net income per share:|
|Proto Labs, Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited)|
|Six Months Ended June 30,|
|Adjustments to reconcile net income to net cash provided by operating activities:|
|Depreciation and amortization||2,768||1,882|
|Stock-based compensation expense||1,620||411|
|Changes in operating assets and liabilities:||(2,838||)||(1,110||)|
|Net cash provided by operating activities||11,478||10,437|
|Purchases of property and equipment||(12,664||)||(6,350||)|
|Purchases of marketable securities||(34,342||)||-|
|Proceeds from sale of marketable securities||250||500|
|Net cash used in investing activities||(46,756||)||(5,850||)|
|Proceeds from initial public offering, net of offering costs||71,530||-|
|Payments on debt, net||(191||)||(3,248||)|
|Proceeds from exercises of warrants and stock options||37||547|
|Net cash provided by (used in) financing activities||71,376||(2,701||)|
|Effect of exchange rate changes on cash and cash equivalents||153||14|
|Net increase in cash and cash equivalents||36,251||1,900|
|Cash and cash equivalents, beginning of period||8,135||6,101|
|Cash and cash equivalents, end of period||$||44,386||$||8,001|
|Proto Labs, Inc. Reconciliation of GAAP to Non-GAAP Financial Measure (In thousands, except share and per share amounts) (Unaudited)|
|Three Months Ended June 30, 2012||Six Months Ended June 30, 2012|
|Non-GAAP net income, adjusted for stock-based compensation expense:|
|GAAP net income||$||5,146||$||9,928|
|Add back: Stock-based compensation expense|
|Cost of revenue||100||145|
|Marketing and sales||110||183|
|Research and development||126||204|
|General and administrative||434||1,088|
|Total stock-based compensation expense||770||1,620|
|Less: Tax benefit on stock-based compensation||(204||)||(469||)|
|Non-GAAP net income||$||5,712||$||11,079|
|Non-GAAP net income per share:|
|Shares used to compute non-GAAP net income per share:|